Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07499193

Study of Blinking as a Function of Tear Film Quality

The goal of this study is to better understand how eye blinking behavior is linked to the stability of the tear film, in adults aged 18 to 65 years, with or without symptoms of dry eye.

The main questions are:

* Do the results of a New Blink Task reflect tear film stability ? * How are the blink related metrics in relation with each other? Researchers will compare two groups of participants-those without dry eye symptoms and those with dry eye symptoms-to see if blinking measures differ between them and whether these measures relate differently to tear film quality.

Participants will:

* Answer a questionnaire about dry eye symptoms * Have their visual correction measured (if they wear glasses) * Undergo non-invasive assessments of tear film quality using an imaging device * Complete three types of blink tasks, each repeated three times, including measurements of blinking and of tear film stability

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

EssilorLuxottica - Neuroscience & Medical Research center

Paris, 94220, France

Location contact

Sarah Marié, MSc

CONTACT

[email protected]

+33177749169

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Volunteer, fluent in French, willing to follow the protocol, able to read and understand the information sheet and provide free and informed consent
  • Covered by a social security
  • Aged between 18 and 65 years inclusive
  • Binocular near visual acuity ≤ 0.3 LogMAR (≥ 5/10) (corrective glasses accepted)

Exclusion criteria

  • Employees of Essilor International, Luxottica, or GrandVision and their subsidiaries
  • Pregnant or breastfeeding women (Article L1121-5)
  • Individuals deprived of liberty by judicial or administrative decision, or hospitalized without consent under Articles L.3212-1 and L.3213-1, who do not fall under Article L.1121-8, and individuals admitted to a health or social care facility for purposes other than research
  • Adults unable or incapable of giving informed consent (Article L1121-8)
  • Participants currently in an exclusion period from another study
  • Participants deemed unfit to participate by the investigator for any reason that may affect subject safety or study integrity All categories of individuals particularly protected under French law are excluded from this research (Articles L1121-5 to L1121-9 of the French Public Health Code).
  • Use of eye drops or ophthalmic solutions within the last 2 hours
  • Wearing contact lenses within the last 48 hours
  • Reported history of severe ocular pathology such as glaucoma, retinitis pigmentosa, diabetic retinopathy, macular involvement, resulting in visual field loss or acuity loss (especially aphakia), except for dry eye (which is not an exclusion criterion)
  • Reported history of eye surgery or trauma to the eye or its adnexa excepted refractive surgery and cataract surgery
  • Reported history of eyelid abnormalities (ptosis)
  • Reported history of neurological deficits, including epilepsy or sensory-motor coordination disorders, vestibular or cerebellar pathology (e.g., balance disorders, nystagmus, Parkinson's disease)
  • Reported history of musculoskeletal disorders preventing maintenance of a fixed head position

Treatment and study plan

Blink behaviour

Other

Single intervention

Primary outcomes

  1. Evaluates the correlation between the Absolute Maximum Eye Aperture Duration measured in seconds and the non-invasive tear film break-up time measured in seconds measured with device IDRA .

    Time frame: Day one

Secondary outcomes

  1. Evaluates the correlation between the Absolute Maximum Eye Aperture Duration measured in seconds with parameters of dry eye ( tears meniscus height (mm), bulbar redness grade (from 0 to 4), blink quality (in %)) measured with device IDRA .

    Time frame: Day one

  2. Compares the coefficient of variation of the Absolute Maximum Eye Aperture Duration (in %) with the coefficient of variation of the non-invasive tear film break-up time (in %) measured with device IDRA .

    Time frame: Day one

  3. Evaluate the effects of ocular surface characteristics, demographics, and task acceptability on two primary outcomes via linear regression model

    Time frame: Day one

    Uses linear regression models to evaluate the effects of ocular surface characteristics (tears meniscus height (mm), bulbar redness grade (from 0 to 4), blink quality (in %) measured with device IDRA , demographics (age and gender), and task acceptability (questionnaire) on two primary outcomes:

    Absolute Maximum Eye Aperture Duration (seconds) and the non-invasive tear film break-up time (seconds)

  4. Evaluate the effects of ocular surface characteristics, demographics, and task acceptability on coefficient of variation of two primary outcomes via linear regression model

    Time frame: Day one

    Uses linear regression models to evaluate the effects of ocular surface characteristics (tears meniscus height (mm), bulbar redness grade (from 0 to 4), blink quality (in %) measured with device IDRA , demographics (age and gender), and task acceptability (questionnaire) on two primary outcomes:

    Absolute Maximum Eye Aperture Duration (seconds) and the non-invasive tear film break-up time (seconds) on coefficient two primary outcomes: Absolute Maximum Eye Aperture Duration (%) and the non-invasive tear film break-up time (%)

Study contacts

Contact information is provided by the study sponsor or research team.

Sarah Marié, MSc

CONTACT

[email protected]

+33177749169

Sponsors and collaborators

Lead sponsor

Essilor International

Industry

Registry information

Official study title

Etude Des Clignements en Fonction de la Qualité du Film Lacrymal

Acronym: WINK

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Mar 30, 2026
Registry last updated
Mar 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.